New therapeutic target for osteoarthritis: modulating immune-metabolic aberrations and micromilieu remodeling in underlying bone
Abstract
Traditionally, osteoarthritis (OA) has been thought of as a degenerative disease mostly caused by mechanical wear and tear. However, recent research suggests that immunometabolic pathways drive the active process of subchondral bone remodeling. According to this study, the immunometabolic axis is a key regulatory network in the subchondral bone microenvironment of osteoarthritis (OA), facilitating metabolic interaction between osteocytes and immune cells like macrophages. Bone homeostasis is destroyed by immune cell infiltration, which also promotes the release of inflammatory mediators and local metabolic reprogramming. These results support the idea that OA is an immunometabolic disease. Intervening in the immunometabolic network of subchondral bone can be accomplished by focusing on immune cell metabolic pathways, particularly those that control the phenotypic transition of M1/M2 macrophages. It is anticipated that this approach will control the immunometabolic dialogue, slow the advancement of osteoarthritis, end the vicious cycle of inflammatory metabolic disorders, and ultimately offer a new approach to treating osteoarthritis.
Read the paper
Related studies
- Irisin Enhances Osteoblast DifferentiationIn Vitro
- Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
- Interaction between Schwann Cells and Osteoblasts In Vitro
- Administration of cinnamaldehyde promotes osteogenesis in ovariectomized rats and differentiation of osteoblast in vitro
- The Effect of the Major Components of Fructus Cnidii on Osteoblasts In Vitro
- Estrogen depletion alters osteogenic differentiation and matrix production by osteoblasts in vitro
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.